Le Lézard
Classified in: Health, Science and technology
Subject: PLW

ADMINISTRATIVE LAW JUDGE ISSUES INITIAL DETERMINATION IN BIO-LAYER INTERFEROMETERS INVESTIGATION


PALO ALTO, Calif., July 6, 2023 /PRNewswire/ -- An Administrative Law Judge at the United States International Trade Commission (USITC) has announced the termination of the Section 337 investigation involving certain biolayer interferometers and components. In October 2022, Sartorius BioAnalytical Instruments, Inc. lodged a complaint with the USITC against Gator Bio, Inc., alleging the infringement of four US patents.

After conducting a thorough analysis, the presiding ALJ determined that the asserted claims of one of patents are invalid due to indefiniteness. Soon after, Sartorius voluntarily moved to terminate the remaining three patents from the investigation. On June 30, 2023, the ALJ issued an order terminating the investigation in its entirety.

Gator Bio holds a deep regard for intellectual property and firmly asserts that our next generation biolayer interferometry technology does not infringe on the intellectual property owned by other entities. We remain committed to continued innovation and the development of a robust product portfolio, while vigorously defending our intellectual property against any future challenges. Our goal is to create innovative products that enhance the productivity of biotherapeutics discovery and development.

About Gator Bio:

Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. The Gator next gen biolayer interferometry (BLI) instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration, and epitope binning, etc. Most importantly, Gator Bio's analytical capabilities enable better and faster characterization of drug candidates and viral vectors, thus providing greater value in drug development and gene therapy applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com

Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 0827
Website: http://www.gatorbio.com//
LinkedIn

SOURCE Gator Bio


These press releases may also interest you

at 02:10
Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the...

at 02:00
Exams can be daunting for students and parents, but with the right approach it can become a rewarding and manageable experience. Expert private tutors can support academic study and exam-readiness while promoting students' mental health with...

at 02:00
As part of its Global Science Summit, the Novo Nordisk Foundation issues an international open call for research projects to catalyse science-based solutions to key global challenges. The programme expects to hand out up to eight grants with a total...

at 02:00
"Nando", a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its...

at 01:27
GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual...

at 01:05
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business...



News published on and distributed by: